Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...

The FDA has granted Breakthrough Device Designation to PreveCol, a blood test for early colorectal cancer detection developed by Amadix. PreveCol excels in identifying precancerous lesions more ...

One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to MONALEESA data presented at SABCS 2025.

Ariceum Therapeutics announced that the US FDA has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial of its proprietary radiolabelled peptide, 225Ac-SSO110 ...

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

Techsomed Medical Technologies announces that the US Food and Drug Administration (FDA) has granted De Novo clearance for its BioTraceIO, an ultrasound-based liver ablation software. This innovative ...

BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...

Early findings from the FANSS study, presented at ESMO Asia 2025, point to a potential shift in how clinicians identify lung cancer in a population that currently lacks formal screening guidelines.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s anti–PD-1 therapy pembrolizumab (KEYTRUDA®), potentially expanding ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...